Literature DB >> 9294163

Phage display of a catalytic antibody to optimize affinity for transition-state analog binding.

M Baca1, T S Scanlan, R C Stephenson, J A Wells.   

Abstract

Catalytic antibodies have shown great promise for catalyzing a tremendously diverse set of natural and unnatural chemical transformations. However, few catalytic antibodies have efficiencies that approach those of natural enzymes. In principle, random mutagenesis procedures such as phage display could be used to improve the catalytic activities of existing antibodies; however, these studies have been hampered by difficulties in the recombinant expression of antibodies. Here, we have grafted the antigen binding loops from a murine-derived catalytic antibody, 17E8, onto a human antibody framework in an effort to overcome difficulties associated with recombinant expression and phage display of this antibody. "Humanized" 17E8 retained similar catalytic and hapten binding properties as the murine antibody while levels of functional Fab displayed on phage were 200-fold higher than for a murine variable region/human constant region chimeric Fab. This construct was used to prepare combinatorial libraries. Affinity panning of these resulted in the selection of variants with 2- to 8-fold improvements in binding affinity for a phosphonate transition-state analog. Surprisingly, none of the affinity-matured variants was more catalytically active than the parent antibody and some were significantly less active. By contrast, a weaker binding variant was identified with 2-fold greater catalytic activity and incorporation of a single substitution (Tyr-100aH --> Asn) from this variant into the parent antibody led to a 5-fold increase in catalytic efficiency. Thus, phage display methods can be readily used to optimize binding of catalytic antibodies to transition-state analogs, and when used in conjunction with limited screening for catalysis can identify variants with higher catalytic efficiencies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9294163      PMCID: PMC23305          DOI: 10.1073/pnas.94.19.10063

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

Review 1.  New perspectives on catalytic antibodies.

Authors:  J W Jacobs
Journal:  Biotechnology (N Y)       Date:  1991-03

2.  Additivity of mutational effects in proteins.

Authors:  J A Wells
Journal:  Biochemistry       Date:  1990-09-18       Impact factor: 3.162

3.  Transition-state characterization: a new approach combining inhibitor analogues and variation in enzyme structure.

Authors:  M A Phillips; A P Kaplan; W J Rutter; P A Bartlett
Journal:  Biochemistry       Date:  1992-02-04       Impact factor: 3.162

Review 4.  Efficient site-directed mutagenesis using uracil-containing DNA.

Authors:  T A Kunkel; K Bebenek; J McClary
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

5.  Antibody humanization using monovalent phage display.

Authors:  M Baca; L G Presta; S J O'Connor; J A Wells
Journal:  J Biol Chem       Date:  1997-04-18       Impact factor: 5.157

6.  Calculation of protein extinction coefficients from amino acid sequence data.

Authors:  S C Gill; P H von Hippel
Journal:  Anal Biochem       Date:  1989-11-01       Impact factor: 3.365

Review 7.  How do enzymes work?

Authors:  J Kraut
Journal:  Science       Date:  1988-10-28       Impact factor: 47.728

8.  Humanization of an anti-p185HER2 antibody for human cancer therapy.

Authors:  P Carter; L Presta; C M Gorman; J B Ridgway; D Henner; W L Wong; A M Rowland; C Kotts; M E Carver; H M Shepard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

9.  Selection of phage antibodies by binding affinity. Mimicking affinity maturation.

Authors:  R E Hawkins; S J Russell; G Winter
Journal:  J Mol Biol       Date:  1992-08-05       Impact factor: 5.469

10.  High level Escherichia coli expression and production of a bivalent humanized antibody fragment.

Authors:  P Carter; R F Kelley; M L Rodrigues; B Snedecor; M Covarrubias; M D Velligan; W L Wong; A M Rowland; C E Kotts; M E Carver
Journal:  Biotechnology (N Y)       Date:  1992-02
View more
  6 in total

1.  Selection for improved subtiligases by phage display.

Authors:  S Atwell; J A Wells
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

2.  Enzyme mimicry by the antiidiotypic antibody approach.

Authors:  A V Kolesnikov; A V Kozyr; E S Alexandrova; F Koralewski; A V Demin; M I Titov; B Avalle; A Tramontano; S Paul; D Thomas; A G Gabibov; A Friboulet
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

3.  Engineering the substrate specificity of the DhbE adenylation domain by yeast cell surface display.

Authors:  Keya Zhang; Kathryn M Nelson; Karan Bhuripanyo; Kimberly D Grimes; Bo Zhao; Courtney C Aldrich; Jun Yin
Journal:  Chem Biol       Date:  2013-01-24

4.  Routes to covalent catalysis by reactive selection for nascent protein nucleophiles.

Authors:  Andrey V Reshetnyak; Maria Francesca Armentano; Natalia A Ponomarenko; Domenica Vizzuso; Oxana M Durova; Rustam Ziganshin; Marina Serebryakova; Vadim Govorun; Gennady Gololobov; Herbert C Morse; Alain Friboulet; Sudesh P Makker; Alexander G Gabibov; Alfonso Tramontano
Journal:  J Am Chem Soc       Date:  2007-11-29       Impact factor: 15.419

5.  Non-antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity.

Authors:  Zenjiro Sampei; Tomoyuki Igawa; Tetsuhiro Soeda; Miho Funaki; Kazutaka Yoshihashi; Takehisa Kitazawa; Atsushi Muto; Tetsuo Kojima; Satoshi Nakamura; Kunihiro Hattori
Journal:  MAbs       Date:  2015       Impact factor: 5.857

Review 6.  Development of designed site-directed pseudopeptide-peptido-mimetic immunogens as novel minimal subunit-vaccine candidates for malaria.

Authors:  José Manuel Lozano; Liliana P Lesmes; Luisa F Carreño; Gina M Gallego; Manuel Elkin Patarroyo
Journal:  Molecules       Date:  2010-12-06       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.